Datopotamab Deruxtecan-Associated Select Adverse Events: Clinical Practices and Institutional Protocols on Prophylaxis, Monitoring, and Management

By afschroeder • July 24, 2025

Lisberg A, Huppert LA, Halmos B, Ledezma B, Soto-Romano V, Traina TA. Datopotamab Deruxtecan-Associated Select Adverse Events: Clinical Practices and Institutional Protocols on Prophylaxis, Monitoring, and Management. Oncologist. 2025 Jul 23:oyaf225. doi: 10.1093/oncolo/oyaf225. Epub ahead of print. PMID: 40700616.

Tags: breast neoplasm, clinical practice patterns, Datopotamab deruxtecan, drug-related side effects and adverse reactions, Hematology/Oncology, lung neoplasm, Publications

Lentivirus-Based Hematopoietic Stem/Progenitor Cell Therapy Provides Effective and Long-Term Treatment in Hypophosphatasia Mouse Model

Carrillo M, Tomer S, Wang L, Cook E, Wennerberg W, Tien N, Ng H, Alagarsamy J, Rezek V, Martin H, Narisawa S, Millan JL, Crine[...]

Pathologic response to neoadjuvant chemotherapy in ovarian cancer and its association with outcome: A surrogate marker of survival

Marsh LA, Kim TH, Zhang M, Kubalanza K, Treece CL, Chase D, Memarzadeh S, Salani R, Karlan B, Rao J, Konecny GE. Pathologic response to[...]

Comparative effectiveness of CDK4/6 inhibitors in metastatic breast cancer: using the target trial emulation framework to investigate overall survival in routine care

Brufsky AM, Finn RS, Metzger O, Goncalves R, Huang-Bartlett C, Sreenivasan S, Nur U, Davies J, Grigorenko A, Long GH. Comparative effectiveness of CDK4/6 inhibitors[...]